Clinical Report: Bracco Targets Cell Therapy Manufacturing with Microbubble Processing
Overview
Bracco Imaging is introducing a microbubble-based technology for cell therapy manufacturing, aiming to replace traditional magnetic beads. This innovation is designed to reduce cellular stress, which can enhance T-cell therapy production efficiency by streamlining cell selection and activation processes.
Background
The advancement of cell therapy manufacturing is crucial for improving patient outcomes and expanding treatment options. Traditional methods often involve complex workflows that can introduce variability and stress to cells, leading to reduced efficacy. Bracco's new approach seeks to address these challenges by providing a cleaner, more efficient method for cell enrichment and activation, which is particularly important as the demand for personalized therapies grows.
Data Highlights
No numerical data is available in the source material, indicating a qualitative focus on the technology's benefits.Key Findings
["Bracco's microbubble technology offers a bead-free alternative for cell selection and activation.", 'The technology minimizes cellular stress and eliminates residual materials that complicate downstream processing.', 'It supports both positive and negative selection strategies for isolating immune cell subsets.', 'The microbubbles can be removed easily, simplifying the workflow compared to traditional bead-based processes.', 'Bracco is building a dedicated cell therapy team to support commercialization and partnerships.']Clinical Implications
The introduction of Bracco's microbubble technology could significantly streamline cell therapy manufacturing processes, making them more efficient and less stressful for cells. This advancement may enhance the scalability and accessibility of personalized therapies, particularly in the context of T-cell therapies, by allowing for more precise control over cell populations.
Conclusion
Bracco Imaging's innovative microbubble-based approach represents a promising development in cell therapy manufacturing, with the potential to improve efficiency, reduce complications in the production of therapeutic cells, and ultimately enhance patient outcomes.
References
- the medicine maker, The Medicine Maker, 2026 -- Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy
- the medicine maker, The Medicine Maker, 2026 -- Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy
- the medicine maker, The Medicine Maker, 2026 -- Manufacturing Inside the Patient
- the medicine maker, The Medicine Maker, 2026 -- New Collaboration to Automate Cell Therapy Manufacturing with Robotics
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PMC
- Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Guidance for Industry
- Bracco Imaging - Cell Therapy
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PMC
- Considerations for the Development of Chimeric Antigen Receptor T Cell Products; Guidance for Industry
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
